Zuraw, B.L., Bernstein, J.A., Lang, D.M., Craig, T., Dreyfus, D., Hsieh, F., et al. (2013) A Focused Parameter Update: Hereditary Angioedema, Acquired C1 Inhibitor Deficiency, and Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Journal of Allergy and Clinical Immunology, 131, 1491-1493.
https://doi.org/10.1016/j.jaci.2013.03.034

has been cited by the following article:

• TITLE: Angiotensin-Converting Enzyme Inhibitor Induced Angioedema Occurring after 8 Years of Taking Lisinopril: A Case Report

  AUTHORS: Wade Jodeh, Gregory Stone

  KEYWORDS: Angioedema, Angiotensin Converting Enzyme Inhibitor, Lisinopril, Eight Years

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.9 No.5, April 22, 2020

  ABSTRACT: Angiotensin-converting enzyme inhibitor induced angioedema (AIIA) can vary from mild to life-threatening. A vast majority of cases of AIIA occur within a month of starting an angiotensin-converting enzyme-inhibitor (ACE-I). We present a 48-year-old male who presented with respiratory failure secondary to AIIA, after being on lisinopril for over 8 years. He had no previous complications secondary to lisinopril and aside from smoking, carried no risk factors for AIIA. Despite conventional treatment for angioedema, he had a prolonged stay in the Medical Intensive Care Unit (MICU). Following discharge, there hasn’t been a recurrence of AIIA since the discontinuation of lisinopril. The case is intended to caution that AIIA remains possible even late into a chronic regimen of ACE-I. This is a risk that shouldn’t be neglected, even with sparse risk factors or longer duration of ACE-I use. Conventional treatment is not currently in line with proposed etiologies of AIIA. We advocate for more clinical trials involving pharmaceutical agents targeting bradykinin accumulation.